Maze Therapeutics Inc logo

Maze Therapeutics Inc

MAZE
Healthcare|Biotechnology|USA
$30.56
-1.89 (-5.82%)
Tangible Book
$6.87

Upcoming Data Readouts (2)

Sep 2026
Est. completion
P2Proteinuric Kidney Disease
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
NCT06830629n=56
Dec 2027
Est. completion
P2Phenylketonuria (PKU)
A Phase 2 Study of MZE782 in Adults With PKU
NCT07694440n=38

Recent Press Releases